IGF-1 LR3

Long Arg3 IGF-1 · R3-IGF-1 · Increlex variant · Long-Acting IGF-1

"IGF-1 with an Arg3 substitution and N-terminal extension that prevents IGFBP binding — extending half-life from minutes to 20–30 hours and enabling full-body systemic IGF-1 activity rather than hepatic clearance. The most widely used IGF-1 variant in the bodybuilding community for muscle hypertrophy, fat loss, and recovery."

Type

83 amino acid IGF-1 variant

Half-life

20–30 hours (vs minutes for base IGF-1)

Status

UK: not illegal to buy or possess · WADA: prohibited at all times · US FDA: not approved · research compound

Key mod

Reduced IGFBP-3 binding → systemic circulation

Protocol summary

Community dose

20–80 mcg/day SubQ

Timing

Post-workout with food

Cycle

4–6 weeks max, equal off

Community-reported

20–80 mcg/day SubQ · post-workout with food · 4–6 week cycles

Hypoglycaemia risk — eat carbs before injection; never combine with insulin

How we read the evidence

Modified IGF-1 with extended half-life · widely used in bodybuilding · zero formal human trials at performance doses · receptor downregulation and cancer-pathway concerns are real

Animal evidence

IGF-1 LR3 is a structurally modified IGF-1 — substitution of glutamic acid for arginine at position 3, plus a 13-amino-acid N-terminal extension. The modifications dramatically reduce IGF binding protein affinity, extending half-life from ~20 minutes (native IGF-1) to 20–30 hours and increasing potency roughly 3× (Tomas et al. 1996). Animal studies show muscle hypertrophy and nutrient partitioning effects via prolonged IGF-1 receptor activation. The mechanism translates the brief native-IGF-1 pulse into a sustained anabolic signal.

Community & clinical practice

Community use is widespread in bodybuilding, with protocols converging on 20–80 mcg SubQ once daily for 4–6 week cycles, followed by equal time off. Beginners start 20–40 mcg/day for the first week to assess hypoglycaemia tolerance. Most users find diminishing returns above 50–60 mcg/day. Women typically run 10–30 mcg/day. Post-workout timing is common to bias uptake toward trained muscle. Cycle length must be limited — 4–6 weeks is the stated upper bound, with 4+ weeks off, to reduce IGF-1 receptor desensitisation and limit cumulative exposure. Always inject with food; the long half-life and insulin-receptor cross-affinity mean hypoglycaemia is a real risk that has caused community emergencies.

Human trial data

No formal human clinical trials at performance doses have been conducted. The pharmacokinetic and potency characterisation comes from preclinical and laboratory work (Tomas et al. 1996 and similar). Mecasermin (native IGF-1, FDA-approved as Increlex) trials inform the safety framework — particularly the hypoglycaemia and tonsillar hypertrophy signals — but cannot be directly extrapolated to LR3 because the modifications produce different pharmacokinetics. Performance-population dose-response is essentially uncharted in formal research.

Regulatory status

Not FDA-approved. Mecasermin (native IGF-1) is FDA-approved for paediatric IGF-1 deficiency — IGF-1 LR3 is not, and the regulatory framework treats them as distinct compounds. WADA-banned for tested athletes. Sourcing via research-peptide vendors with significant purity and potency variation between products. Theoretical concerns include accelerated growth of pre-existing or precancerous cells via sustained IGF-1 receptor activation — the chronic-elevation cancer-pathway concern is real, even if unobserved in short-cycle community use. Bone and organ growth (gut distension, jaw growth) reported anecdotally with prolonged high-dose use are irreversible.

Convergence

IGF-1 LR3 has a clean mechanism (sustained IGF-1 receptor activation via reduced binding-protein affinity) and a strong anabolic signal at moderate doses, but no formal human safety data at performance doses. Standard community protocol: 20–80 mcg/day SubQ for 4–6 weeks, equal off, always with food, never approaching the gut/organ-growth doses some bodybuilders use. Pep IQ flags this as one of the higher-risk peptides on the platform: hypoglycaemia is real and immediate, the cancer-pathway concern is genuine even if unproven, and the community marketing significantly understates both. Stay short-cycle, stay moderate-dose, monitor glucose, and recognise this is uncharted human pharmacology.

Origin & Background

The IGF-1 the community actually uses

Base IGF-1 (insulin-like growth factor 1) has an almost comically short half-life in circulation — typically 5–10 minutes as a free peptide before it is either bound by one of six IGF-binding proteins (IGFBPs) or cleared by the liver. This renders direct IGF-1 injection impractical for most bodybuilding and performance applications: the window of activity is so brief that site injections near target tissue are required, and even then the systemic exposure is minimal. This is why the IGF-1 in GH protocols works via the sustained hepatic production stimulated by GH — not via the brief free IGF-1 pulse itself.

IGF-1 LR3 (Long Arg3 IGF-1) solves this problem through two modifications: (1) an Arg3 substitution at position 3 of the mature IGF-1 sequence, which significantly reduces binding to IGFBP-3 (the principal binding protein that sequesters circulating IGF-1), and (2) a 13-amino-acid N-terminal extension peptide. Together these modifications extend half-life to 20–30 hours and enable the peptide to circulate freely in systemic blood rather than being immediately sequestered or cleared. The result: one daily or alternate-day injection produces sustained, whole-body IGF-1 receptor activation rather than a brief localised stimulus.

IGF-1 LR3 was originally developed for research purposes — including studying IGF-1 biology without the confound of rapid clearance. Its adoption by the bodybuilding community predates most other research peptides and reflects the community's early recognition that the pharmacokinetics, not the receptor binding, were the limiting factor in using IGF-1 therapeutically.

Why this is a fundamentally different compound to base IGF-1: When you read IGF-1 research using native IGF-1, the pharmacokinetics are completely different. LR3 produces 20–30 hours of free IGF-1 receptor stimulation from a single injection. Base IGF-1 produces minutes. Every clinical application, every dose-response relationship, every safety consideration differs between the two. The entry for IGF-1 in this book covers the receptor biology and physiology; this entry covers the distinct pharmacology of LR3 specifically.

Science & Mechanism

IGFBP evasion — 20–30 hours of free IGF-1 activity

Mechanism of Action

Reduced IGFBP-3 binding: The Arg3 substitution reduces affinity for IGFBP-3, the principal binding protein that sequesters ~80% of circulating IGF-1 in a ternary complex with ALS (acid-labile subunit). By evading this binding, LR3 circulates as free peptide rather than bound reservoir — maintaining receptor-accessible concentrations for 20–30 hours post-injection.

IGF-1R activation (same receptor): IGF-1 LR3 binds the same IGF-1 receptor (IGF-1R) as native IGF-1 with comparable affinity. IGF-1R is a receptor tyrosine kinase — binding triggers autophosphorylation → IRS-1 → PI3K/Akt (hypertrophy, survival, glucose uptake) and MAPK/ERK (proliferation, differentiation) pathways. The hypertrophy signal is potent and operates in skeletal muscle, cardiac muscle, and virtually every other tissue.

Systemic vs local delivery: Because LR3 circulates systemically for 20–30 hours, it stimulates IGF-1R throughout the body — skeletal muscle, connective tissue, bone, and organs simultaneously. Base IGF-1 injected locally acts primarily at the injection site before being cleared. LR3 produces a more anabolic whole-body environment but also activates IGF-1R in all tissues, including any with elevated proliferative potential.

Glucose transport and partitioning: IGF-1R activation stimulates GLUT4 translocation and glucose uptake in muscle independently of insulin. LR3's 20–30 hour activity window produces sustained insulin-like glucose partitioning into muscle — lowering blood glucose and directing carbohydrate calories toward glycogen synthesis and lean tissue. This effect is dose-dependent and can cause hypoglycaemia at higher doses.

Satellite cell activation: IGF-1 is the principal driver of skeletal muscle satellite cell activation — the muscle stem cells that fuse with fibres to enable true hypertrophy beyond myofibrillar volume changes. LR3's prolonged systemic exposure maximises satellite cell signalling, potentially enabling more structural muscle growth than brief-acting IGF-1 preparations.

Things to know

Risks — hypoglycaemia is real

Serious

Hypoglycaemia — dose-dependent glucose-partitioning into muscle can cause symptomatic hypoglycaemia. Highest risk: fasted administration, high doses (>80mcg), overnight. Always eat 30–50g carbohydrates with or immediately after injection. Keep glucose tablets or fast-acting sugar accessible. Monitor blood glucose if using above 50mcg.

Serious

Insulin-like interactions — do not combine with insulin without precise glucose monitoring. Additive hypoglycaemia risk is extremely dangerous. IGF-1 LR3 and insulin should not be used together without expert supervision and continuous glucose monitoring.

Moderate

Proliferative risk (long-term) — systemic IGF-1R activation at supraphysiological levels for extended periods stimulates cellular proliferation broadly. The theoretical cancer promotion risk — well-documented in epidemiological studies linking chronically elevated IGF-1 to cancer incidence — is amplified by LR3's 20–30 hour systemic activity. Cycle length should be limited; anyone with a personal or family cancer history should not use LR3.

Moderate

Organ and tissue growth — IGF-1R is expressed in all tissues. Prolonged supraphysiological exposure can increase organ size (gut hypertrophy, cardiac hypertrophy at very high doses). Gut hypertrophy from prolonged IGF-1 excess is the "GH gut" phenomenon familiar to the bodybuilding community.